Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm phase 2 study of tisotumab vedotin in recurrent or metastatic cervical cancer
2017-003413-25Phase 2Completed
- Sponsor
- Genmab
- Start
- Feb 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisotumab vedotin in cervical cancer (mCC), sponsored by Genmab. Primary endpoint: Confirmed objective response rate. Started Feb 2018; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on 2017-003413-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003413-25.